Published in Proc Natl Acad Sci U S A on May 26, 1998
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev (2011) 5.20
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A (2000) 3.86
LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell (2011) 3.78
Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell (2012) 3.39
Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci U S A (2005) 3.37
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A (2004) 2.89
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron (2015) 2.82
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A (2002) 2.81
T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature (2017) 2.70
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem (2010) 2.67
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat (2010) 2.29
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J Mol Biol (2009) 2.14
Structural and functional characterization of two alpha-synuclein strains. Nat Commun (2013) 2.05
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem (2010) 1.94
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet (2013) 1.94
Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem (2010) 1.92
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One (2009) 1.88
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med (2014) 1.85
Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology (2004) 1.82
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A (2001) 1.80
Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A (1999) 1.73
Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol (2015) 1.71
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.70
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol (2003) 1.67
Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. Mol Biol Cell (2006) 1.67
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem (2008) 1.65
The function of α-synuclein. Neuron (2013) 1.63
Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) 1.63
α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.62
Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem (2009) 1.57
Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A (2009) 1.56
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci (2015) 1.52
Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int J Cell Biol (2012) 1.52
Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry (2010) 1.50
Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell (2008) 1.48
The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.44
Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol (2007) 1.43
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys J (2012) 1.42
Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci (2005) 1.41
shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. PLoS Genet (2016) 1.40
Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe. Mol Neurodegener (2016) 1.40
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (2003) 1.40
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain (2010) 1.38
Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci (2008) 1.38
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol (2017) 1.37
Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet (2009) 1.37
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener (2012) 1.34
Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta (2010) 1.34
Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. J Mol Biol (2008) 1.33
Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun (2006) 1.32
Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife (2013) 1.31
Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem (2009) 1.29
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol (2008) 1.26
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis (2012) 1.25
Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J (1999) 1.25
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A (2013) 1.24
HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One (2008) 1.23
A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. Protein Sci (2007) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci (1999) 1.21
Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One (2011) 1.21
CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis (2008) 1.19
alpha-Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcohol-preferring and -nonpreferring rats. Proc Natl Acad Sci U S A (2003) 1.18
Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol (2008) 1.18
Molecular determinants of the aggregation behavior of alpha- and beta-synuclein. Protein Sci (2008) 1.17
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol (2006) 1.17
α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci (2011) 1.16
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron (1989) 8.04
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry (1996) 6.47
Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol (1996) 4.54
A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A (1990) 4.26
Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron (1992) 4.22
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Lewy bodies of Parkinson's disease contain neurofilament antigens. Science (1983) 2.70
Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol (1988) 2.59
Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci U S A (1991) 2.21
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res (1997) 2.05
Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci U S A (1988) 2.04
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (1988) 2.01
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
Pathology and biology of the Lewy body. J Neuropathol Exp Neurol (1993) 1.99
Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol (1976) 1.97
Ultrastructural observations in Parkinsonism. J Pathol (1969) 1.94
Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol (1961) 1.90
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol (1991) 1.86
Image reconstruction of the Alzheimer paired helical filament. EMBO J (1985) 1.82
Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology (1991) 1.69
Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol (1992) 1.55
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol (1996) 1.47
Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain (1987) 1.44
Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol (1976) 1.44
Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A (1990) 1.42
Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain. Proc Natl Acad Sci U S A (1988) 1.41
Microtubule minus ends can be labelled with a phage display antibody specific to alpha-tubulin. J Mol Biol (1996) 1.21
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J Mol Evol (1985) 47.78
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data, and the branching order in hominoidea. J Mol Evol (1989) 16.24
CONSEL: for assessing the confidence of phylogenetic tree selection. Bioinformatics (2001) 11.90
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Evolutionary relationship of archaebacteria, eubacteria, and eukaryotes inferred from phylogenetic trees of duplicated genes. Proc Natl Acad Sci U S A (1989) 8.45
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron (1989) 8.04
Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature (1997) 7.32
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet (1998) 6.09
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
Procedures for three-dimensional reconstruction of spherical viruses by Fourier synthesis from electron micrographs. Philos Trans R Soc Lond B Biol Sci (1971) 4.75
Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A (1988) 4.68
Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A (1988) 4.45
The crystal structure of the human hepatitis B virus capsid. Mol Cell (1999) 4.36
Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron (1992) 4.22
Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature (1996) 4.12
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A (2000) 3.86
Cingulin, a new peripheral component of tight junctions. Nature (1988) 3.81
Gene transfer to the nucleus and the evolution of chloroplasts. Nature (1998) 3.79
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Model of amino acid substitution in proteins encoded by mitochondrial DNA. J Mol Evol (1996) 3.53
On the structure of coated vesicles. J Mol Biol (1976) 3.47
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J (1990) 3.36
IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology (2010) 3.34
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
Ribosomal RNA trees misleading? Nature (1993) 3.04
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Models of amino acid substitution and applications to mitochondrial protein evolution. Mol Biol Evol (1998) 3.03
Assembly and packing of clathrin into coats. J Cell Biol (1981) 2.88
Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology (2008) 2.85
Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol (1998) 2.73
Structure and assembly of coated vesicles. Annu Rev Biophys Biophys Chem (1987) 2.65
Molecular clock of silent substitution: at least six-fold preponderance of silent changes in mitochondrial genes over those in nuclear genes. J Mol Evol (1982) 2.58
Harmonic analysis of electron microscope images with rotational symmetry. J Mol Biol (1971) 2.55
Towards resolving the interordinal relationships of placental mammals. Syst Biol (1999) 2.53
The mas oncogene encodes an angiotensin receptor. Nature (1988) 2.53
Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A (1988) 2.53
Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer (2001) 2.46
Plastid genome phylogeny and a model of amino acid substitution for proteins encoded by chloroplast DNA. J Mol Evol (2000) 2.45
Essential role of the small GTPase Rac in disease resistance of rice. Proc Natl Acad Sci U S A (2001) 2.45
Expression cloning of a novel Gal beta (1-3/1-4) GlcNAc alpha 2,3-sialyltransferase using lectin resistance selection. J Biol Chem (1993) 2.40
Evolution of RNA polymerases and branching patterns of the three major groups of Archaebacteria. J Mol Evol (1991) 2.38
Tau protein pathology in neurodegenerative diseases. Trends Neurosci (1998) 2.37
A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature (1993) 2.33
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Three dimensional reconstructions of spherical viruses by fourier synthesis from electron micrographs. Nature (1970) 2.29
Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett (1998) 2.26
On the maximum likelihood method in molecular phylogenetics. J Mol Evol (1991) 2.26
DNA sequence of the tail fibre genes 36 and 37 of bacteriophage T4. J Mol Biol (1981) 2.23
Three-dimensional structure of clathrin cages in ice. EMBO J (1986) 2.22
Location of the 100 kd-50 kd accessory proteins in clathrin coats. EMBO J (1986) 2.21
Active site titration and aminoacyl adenylate binding stoichiometry of aminoacyl-tRNA synthetases. Biochemistry (1975) 2.18
Retroposon analysis of major cetacean lineages: the monophyly of toothed whales and the paraphyly of river dolphins. Proc Natl Acad Sci U S A (2001) 2.11
Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 2.09
Detection of beta-lactamase production by gram-negative bacteria. J Antibiot (Tokyo) (1976) 2.06
Subunit structure of paired helical filaments in Alzheimer's disease. J Cell Biol (1985) 2.06
Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett (1999) 2.05
The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci (2000) 2.03
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A (1993) 1.99
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A (1996) 1.94
A method for monitoring the collapse of plastic sections as a function of electron dose. Ultramicroscopy (1988) 1.93
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ (1998) 1.92
A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol (2000) 1.92
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89
A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett (1999) 1.88
High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet (1999) 1.87
Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene (1999) 1.86
Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol (2015) 1.86
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J (1994) 1.85
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84